Clinical Scorecard: Severe Cases of Myocarditis Linked to Parvovirus B19 in Pediatric Patients During the Post-COVID-19 Period: A Multicenter Observational Study

At a Glance

Key Highlights

• Significant increase in severe parvovirus B19 myocarditis cases in children during 2024, coinciding with increased viral circulation post-COVID-19.
• High severity with 93% requiring intensive care, 89% receiving inotropes, 70% invasive ventilation, and 15% extracorporeal membrane oxygenation.
• Myocarditis presents with severely impaired systolic function (median ejection fraction 25%) and common symptoms include difficulty breathing and fatigue; fever and rash are uncommon.

Guideline-Based Recommendations

Diagnosis

• Perform blood parvovirus B19 PCR testing in all children presenting with severe myocarditis.
• Include serology (IgG and IgM) as part of syndromic screening despite low IgM positivity rates.
• Consider endomyocardial biopsy PCR in select cases to confirm diagnosis.

Management

• Provide intensive care support including inotropes and invasive ventilation as needed.
• Use extracorporeal membrane oxygenation for refractory cases.
• Consider intravenous immunoglobulin therapy in severe disease.
• Postdischarge management may include aspirin, diuretics, ACE inhibitors, β-blockers, ivabradine, and anticoagulation for left ventricular thrombi.

Monitoring & Follow-up

• Monitor cardiac function via echocardiogram or cardiac MRI.
• Continuous cardiac rhythm monitoring for arrhythmias and heart block.
• Follow-up for ongoing cardiac management and recovery.

Risks

• High risk of severe cardiac dysfunction requiring intensive care.
• Potential for cardiac arrest and need for pacemaker insertion due to heart block.
• Prolonged intensive care and inotropic support with possible long-term cardiac sequelae.

Patient & Prescribing Data

Pediatric patients with parvovirus B19–associated myocarditis requiring intensive care

Majority require inotropes and ventilation; intravenous immunoglobulin used in severe cases; ongoing cardiac medications postdischarge common for survivors.

Clinical Best Practices

• Include parvovirus B19 PCR and serology in diagnostic workup for children with severe myocarditis.
• Early intensive care admission and supportive management are critical due to high severity.
• Screen for and manage coinfections and noninfective causes of myocarditis per local guidelines.
• Provide multidisciplinary follow-up for cardiac function and medication management after discharge.

References

• European Centre for Disease Prevention and Control Alert on Parvovirus B19
• UK Health Security Agency Parvovirus B19 Circulation Report